DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 10,383,930
|Title:||Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers|
|Abstract:||A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.|
|Inventor(s):||Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munchen Schwabing, DE), Muller; Phillip (Kassel, DE), Leibold; Julia (Langkampfen, AT), Goldfinger; Valentina (Tubingen, DE)|
|Assignee:||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)|
|Patent Claims:||1. A method of eliciting an immune response in a patient who has prostate cancer, comprising administering to said patient a population of activated T cells that
selectively recognize cells, which present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49), wherein the peptide is in a complex with an MHC molecule, wherein the activated T cells are cytotoxic T cells produced by
contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell, wherein the activated T cells
are expanded in vitro in the presence of an anti-CD28 antibody and IL-12.
2. The method of claim 1, wherein the T cells are autologous to the patient.
3. The method of claim 1, wherein the T cells are obtained from a healthy donor.
4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1, wherein the MHC molecule is a class I MHC molecule.
6. The method of claim 1, wherein the activated T cells are expanded in the presence of IL-12.
7. The method of claim 1, wherein the antigen presenting cell is infected with recombinant virus expressing the peptide.
8. The method of claim 7, wherein the antigen presenting cell is a dendritic cell or a macrophage.
9. The method of claim 1, wherein the contacting is in vitro.
10. The method of claim 1, wherein the population of activated T cells are administered in the form of a composition.
11. The method of claim 10, wherein the composition further comprises an adjuvant.
12. The method of claim 11, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formations formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
13. The method of claim 1, wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49).
14. The method of claim 13, wherein the immune response comprises a cytotoxic T cell response.
15. The method of claim 1, wherein the antigen presenting cell is a particle coated with the peptide in a complex with an WIC class I molecule, wherein the particle is polystyrene particle.
16. The method of claim 15, wherein the particle further comprises an anti-CD28 antibody.
Summary for Patent: Start Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||1513921.5||Aug 6, 2015|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||Start Trial||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||2035-08-06||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||Start Trial||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||2035-08-06||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.